Sentien Biotechnologies said this week it received an Investigational New Drug approval for its SBI-101 drug-device combination product meant for treating individuals with acute kidney injury. The multi-center, Phase 1/2 trial will be the the 1st for the company, and will examine its platform which uses a blood filtering device containing mesenchymal stromal cells for […]
Sentien Biotechnologies
Sentien raises $12m Series A for drug-device combo for acute kidney injury
Sentien Biotechnologies said today that it closed a $12 million Series A financing round, co-led by Boehringer-Ingelheim Venture Fund USA, Inc. and BioInnovation Capital. Chiesi Ventures, MBL Venture Capital Co. and Mass Medical Angels also contributed to the round. The Cambridge, Mass.-based company said it plans to use the funds for initial clinical development of […]
